Pediatrics
Latest News
JAK-inhibitor safety in adolescents with AD: Long-term analyses reported
For abrocitinib, "we're starting to get good numbers of [adolescents] who've had about 2 years of exposure," Dr. Lawrence Eichenfield said.
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.
Latest News
AD in infancy: Diagnostic advice and treatment tips
Among infants who are growing well and otherwise healthy, the infantile eczema phenotype encompasses AD, seborrheic dermatitis, contact dermatitis...
Latest News
Facial, hand, and foot dermatitis: Lebrikizumab and dupilumab show efficacy in new studies
"Lebrikizumab was efficacious in clearing and improving facial and hand dermatitis, burdensome and difficult-to-treat areas, in most patients," Dr...
Conference Coverage
Can this tool forecast peanut allergies?
The predictive scorecard captures 14 images from one infant of mixed race, two White infants, two Black infants, and two Hispanic infants.
Latest News
Scarred med student inspired by dermatologist who treated her
In 2020, Ms. Harris had finished studying at a friend’s apartment when the rescue dog the friend adopted lunged at her, biting her on the face.
Latest News
Contact allergens lurk in diabetes devices
Some reports suggest that at any given time, skin complications may affect as many as one quarter to one half of patients who use diabetes devices...
Latest News
Beware the hidden allergens in nutritional supplements
A detailed history of supplement use is important, as it may reveal possible allergens as the cause of previously unidentified reactions.
Photo Challenge
Scalp Nodule Associated With Hair Loss
A 9-year-old boy presented with a soft subcutaneous nodule with overlying alopecia on the right parietal scalp of 5 months’ duration that had...
Conference Coverage
Meta-analysis examines cancer risk concern for JAK inhibitors
Although no increased cancer risk was seen vs. methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than...